AN2 Therapeutics, Inc. (ANTX) 10-Year Financial Performance & Capital Metrics

ANTX • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.Show more

Revenue $0
EBITDA $0
Net Income -$51M +20.7%
EPS (Diluted) -1.72 +37.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -49.69% +15.5%
ROIC -48.26% +18.1%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 26.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM44.01%

EPS CAGR

10Y-

5Y-

3Y-

TTM45.1%

ROCE

10Y Avg-162.07%

5Y Avg-82.34%

3Y Avg-56.61%

Latest-52.82%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	77K	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	-77K	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	1%	-
Operating Expenses+	31.07M	7.28M	21.57M	42.19M	69.64M	54.55M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.73M	1.26M	4.67M	12.75M	14.76M	14.07M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	29.33M	6.02M	16.91M	29.51M	54.87M	40.49M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-31.07M	-7.28M	-21.57M	-42.26M	-69.64M	-54.55M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.77%	-1.96%	-0.96%	-0.65%	0.22%
EBITDA+	0	0	-21.57M	-42.19M	0	0
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-0.96%	1%	-
D&A (Non-Cash Add-back)	31.07M	7.28M	0	77K	69.64M	54.55M
EBIT	-31.07M	-13.6M	-21.57M	-40.96M	-64.73M	-51.32M
Net Interest Income+	0	3K	69K	837K	0	5.47M
Interest Income	0	3K	69K	1.35M	0	5.47M
Interest Expense	0	0	0	514K	0	0
Other Income/Expense	-2.74M	-6.32M	31K	1.31M	4.9M	3.23M
Pretax Income+	-33.81M	-13.6M	-21.54M	-40.96M	-64.73M	-51.32M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-33.81M	-13.6M	-21.54M	-40.96M	-64.73M	-51.32M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	0.6%	-0.58%	-0.9%	-0.58%	0.21%
Net Income (Continuing)	-33.81M	-13.6M	-21.54M	-40.96M	-64.73M	-51.32M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.30	-0.78	-1.50	-2.79	-2.74	-1.72
EPS Growth %	-	-1.6%	-0.92%	-0.86%	0.02%	0.37%
EPS (Basic)	-0.30	-0.78	-1.50	-2.79	-2.74	-1.72
Diluted Shares Outstanding	18.74M	18.74M	18.74M	15.34M	23.6M	29.83M
Basic Shares Outstanding	18.74M	18.74M	18.74M	15.34M	23.6M	29.83M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.7M	4.23M	60.11M	98.62M	110.51M	86.26M
Cash & Short-Term Investments	5.6M	4.07M	58.55M	96.06M	107.3M	83.62M
Cash Only	5.6M	4.07M	12.1M	27.22M	15.65M	21.35M
Short-Term Investments	0	0	46.46M	68.84M	91.65M	62.27M
Accounts Receivable	0	0	0	0	1.4M	300K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	82K	0	0	2.56M	0	2.34M
Total Non-Current Assets+	0	0	5.21M	3.94M	28.24M	5.83M
Property, Plant & Equipment	0	0	0	53K	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	3.49M	3.22M	27.19M	5.02M
Other Non-Current Assets	0	0	1.72M	667K	1.04M	804K
Total Assets+	5.7M	4.23M	65.32M	102.56M	138.74M	92.09M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.26%	14.43%	0.57%	0.35%	-0.34%
Total Current Liabilities+	159K	1.46M	3.4M	7.19M	14.04M	10.24M
Accounts Payable	51K	132K	1.06M	2.12M	2.68M	3.32M
Days Payables Outstanding	-	-	-	10.06K	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	14K	330K	6K	4.69M	2.47M
Current Ratio	35.85x	2.90x	17.70x	13.72x	7.87x	8.43x
Quick Ratio	35.85x	2.90x	17.70x	13.72x	7.87x	8.43x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	728K	24K	13K	2K	0	0
Long-Term Debt	728K	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	24K	13K	2K	0	0
Total Liabilities	887K	1.48M	3.41M	7.19M	14.04M	10.24M
Total Debt+	728K	0	0	53K	0	0
Net Debt	-4.87M	-4.07M	-12.1M	-27.17M	-15.65M	-21.35M
Debt / Equity	0.15x	-	-	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-82.22x	-	-
Total Equity+	4.81M	2.75M	61.91M	95.37M	124.7M	81.85M
Equity Growth %	-	-0.43%	21.5%	0.54%	0.31%	-0.34%
Book Value per Share	0.26	0.15	3.30	6.22	5.28	2.74
Total Shareholders' Equity	4.81M	2.75M	61.91M	95.37M	124.7M	81.85M
Common Stock	0	0	0	0	0	0
Retained Earnings	-5.8M	-20.32M	-47.38M	-89.72M	-154.46M	-205.78M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-27K	-374K	275K	31K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.49M	-5.36M	-20.48M	-33.46M	-53.29M	-49.26M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-1.16%	-2.82%	-0.63%	-0.59%	0.08%
Net Income	-5.63M	-13.6M	-21.54M	-40.96M	-64.73M	-51.32M
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	0	40K	974K	4.39M	8.41M	8.34M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	3.16M	6.97M	53K	-615K	-2.8M	-3.28M
Working Capital Changes	-10K	1.22M	32K	3.72M	5.83M	-3M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	-16K	81K	417K	2.5M	553K	641K
Cash from Investing+	0	0	-50.02M	-21.77M	-43.28M	54.59M
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	8.08M	3.84M	78.53M	70.36M	84.99M	372K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	64K	-1.2M	-11K	465K	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-2.49M	-5.36M	-20.48M	-33.46M	-53.29M	-49.26M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-1.16%	-2.82%	-0.63%	-0.59%	0.08%
FCF per Share	-0.13	-0.29	-1.09	-2.18	-2.26	-1.65
FCF Conversion (FCF/Net Income)	0.07x	0.39x	0.95x	0.82x	0.82x	0.96x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-702.47%	-359.68%	-66.64%	-52.08%	-58.83%	-49.69%
Return on Invested Capital (ROIC)	-	-	-66.73%	-53.72%	-58.93%	-48.26%
Debt / Equity	0.15x	-	-	0.00x	-	-
Interest Coverage	-	-	-	-82.22x	-	-
FCF Conversion	0.07x	0.39x	0.95x	0.82x	0.82x	0.96x

Frequently Asked Questions

Growth & Financials

AN2 Therapeutics, Inc. (ANTX) grew revenue by 0.0% over the past year. Growth has been modest.

AN2 Therapeutics, Inc. (ANTX) reported a net loss of $34.0M for fiscal year 2024.

Dividend & Returns

AN2 Therapeutics, Inc. (ANTX) has a return on equity (ROE) of -49.7%. Negative ROE indicates the company is unprofitable.

AN2 Therapeutics, Inc. (ANTX) had negative free cash flow of $29.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener